13 completed, 3 active not recruiting. 16 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 16 | Completed 13, Active not recruiting 3 |
| Phase 2 | 4 | Active not recruiting 3, Completed 1 |
Follow Hereditary Angioedema: new trials by email Literature Review of Hereditary Angioedema trials Research Report on Hereditary Angioedema
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema Navenibart - Hereditary Angioedema | Phase 1 / Phase 2 | Completed | Astria Therapeutics, Inc. | 29 | 2023-02-21 | 2026-05-08 |
| Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients ADX-324, Placebo - Hereditary Angioedema | Phase 1 / Phase 2 | Active not recruiting | ADARx Pharmaceuticals, Inc. | 53 | 2022-12-14 | 2026-06-16 |
| A Study of STAR-0215 in Healthy Adult Participants STAR-0215 (SC), Placebo (SC), STAR-0215 (IV) - Hereditary Angioedema | Phase 1 | Completed | Astria Therapeutics, Inc. | 41 | 2022-07-27 | 2024-01-11 |
| A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema Dose 1 of BMN 331, Dose 2 of BMN 331, Dose 3 of BMN 331 - Hereditary Angioedema, HAE | Phase 1 / Phase 2 | Active not recruiting | BioMarin Pharmaceutical | 44 | 2022-02-15 | 2024-05-16 |
| NTLA-2002 in Adults With Hereditary Angioedema (HAE) Biological NTLA-2002, Normal Saline IV Administration - Hereditary Angioedema | Phase 1 / Phase 2 | Active not recruiting | Intellia Therapeutics | 37 | 2021-12-10 | 2026-09-25 |
| Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations KVD824 Prototype 1 modified-release tablet, KVD824 Prototype 2 modified-release tablet, KVD824 Immediate-Release Capsule - Hereditary Angioedema | Phase 1 | Completed | KalVista Pharmaceuticals, Ltd. | 37 | 2020-05-19 | 2021-11-12 |
| Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers GNR-038, 25 МЕ/kg, GNR-038, 50 МЕ/kg, GNR-038, 100 МЕ/kg - Hereditary Angioedema | Phase 1 | Completed | AO GENERIUM | 36 | 2020-03-10 | 2020-09-30 |
| A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers KVD824, Placebo to KVD824 - Hereditary Angioedema | Phase 1 | Completed | KalVista Pharmaceuticals, Ltd. | 108 | 2019-02-12 | 2022-02-17 |
| A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers KVD900, Placebo to KVD900 - Hereditary Angioedema | Phase 1 | Completed | KalVista Pharmaceuticals, Ltd. | 84 | 2018-01-04 | 2025-04-29 |
| A Relative Bioavailability Study of Two Formulations of BCX7353 BCX7353 - Hereditary Angioedema | Phase 1 | Completed | BioCryst Pharmaceuticals | 24 | 2017-02-27 | 2020-01-27 |
| A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions BCX7353, Digoxin, BCX7353 + digoxin - Hereditary Angioedema | Phase 1 | Completed | BioCryst Pharmaceuticals | 54 | 2017-02-17 | 2017-10-26 |
| An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe Substrates BCX7353 and probes - Hereditary Angioedema | Phase 1 | Completed | BioCryst Pharmaceuticals | 20 | 2016-03-01 | 2017-01-31 |
| First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese Volunteers BCX7353, Placebo to match BCX7353 - Hereditary Angioedema | Phase 1 | Completed | BioCryst Pharmaceuticals | 122 | 2015-05-01 | 2016-01-13 |
| Study to Determine How BCX4161 is Metabolized and Eliminated by the Body BCX4161 - Hereditary Angioedema | Phase 1 | Completed | BioCryst Pharmaceuticals | 7 | 2014-08-01 | 2014-10-29 |
| A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161 BCX4161 - Hereditary Angioedema | Phase 1 | Completed | BioCryst Pharmaceuticals | 28 | 2014-04-01 | 2014-08-15 |
| Pharmacokinetics of C1 Esterase Inhibitor in Hereditary Angioedema Subjects C1 esterase inhibitor [human] (C1INH-nf) - Hereditary Angioedema | Phase 1 | Completed | Shire | 27 | 2006-10-09 | 2021-06-03 |
Angioedemas, Hereditary (16) · Angioedema (3) · Cardiovascular Diseases (1) · Genetic Diseases, Inborn (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Skin Diseases (1) · Skin Diseases, Vascular (1) · Urticaria (1) · Vascular Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16) · Hereditary Complement Deficiency Diseases (16) · Immunologic Deficiency Syndromes (16) · Primary Immunodeficiency Diseases (16) · Skin and Connective Tissue Diseases (16) · Cardiovascular Diseases (15) · Genetic Diseases, Inborn (15) · Hypersensitivity (15) · Hypersensitivity, Immediate (15) · Immune System Diseases (15) · Skin Diseases (15) · Skin Diseases, Vascular (15) · Urticaria (15) · Vascular Diseases (15) · Angioedema (13)
berotralstat (4) · avoralstat (2) · Complement C1 Inhibitor Protein (1) · Cyclosporine (1) · Digoxin (1) · RNA, Small Interfering (1) · Rosuvastatin Calcium (1) · Sodium Chloride (1) · sebetralstat (1)
BioCryst Pharmaceuticals (6) · KalVista Pharmaceuticals, Ltd. (3) · Astria Therapeutics, Inc. (2) · ADARx Pharmaceuticals, Inc. (1) · AO GENERIUM (1) · BioMarin Pharmaceutical (1) · Intellia Therapeutics (1) · Shire (1)
United Kingdom (11) · United States (4) · Australia (3) · Germany (2) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Netherlands (1) · New Zealand (1) · Russia (1) · Spain (1)
Joanne Collier, MBChB, FFPM, Dip Stats (OU) (2) · Firas Almazedi, MBChB, Msc, CPI (1) · Joanne Collier (1) · Lauge Farnaes, MD (1) · Litza McKenzie, MBChB (1) · Litza McKenzie, MBChB, BScMedSci (1) · Oksana A. Markova, MD (1)
PMID 35086692, PMID 38294975, PMID 39445704, PMID 40158724, PMID 41794053